Compared with other ablative therapies, stereotactic body radiotherapy might offer a ‘particularly advantageous option’ for ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

A study identified a link between sex hormones and renal cell carcinoma, suggesting potential new treatment strategies.

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...

The following is a summary of “Metabolic syndrome and increased susceptibility to renal cell carcinoma – a meta-analysis,” ...

In an interview, Regina Barragan-Carrillo, MD, highlighted the ongoing global disparities in renal cell carcinoma clinical ...

A longstanding scientific belief about a link between cancer prevalence and animal body size has been tested for the first ...

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell ...

A clinical trial demonstrates that personalised cancer vaccines effectively target mutations in high-risk kidney cancer, ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to a session on the current state and future directions of ...